Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.

Original languageEnglish (US)
Pages (from-to)1335-1341
Number of pages7
JournalAnnals of Oncology
Volume11
Issue number10
DOIs
StatePublished - Nov 23 2000

Fingerprint

Pemetrexed
Folic Acid Antagonists
Neoplasms
gemcitabine
Hydroxymethyl and Formyl Transferases
Clinical Pharmacology
Enzymes
Folic Acid
Non-Small Cell Lung Carcinoma
Colonic Neoplasms
Cisplatin
Pancreas
Urinary Bladder
Neck
Head
Breast Neoplasms
Carcinoma
DNA

Keywords

  • Multitargeted antifolate
  • Solid tumors
  • Thymidylate synthase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pemetrexed : A multitargeted antifolate agent with promising activity in solid tumors. / Adjei, Alex.

In: Annals of Oncology, Vol. 11, No. 10, 23.11.2000, p. 1335-1341.

Research output: Contribution to journalArticle

@article{a21ae0b179dc43e68895d87390021df6,
title = "Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors",
abstract = "Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.",
keywords = "Multitargeted antifolate, Solid tumors, Thymidylate synthase",
author = "Alex Adjei",
year = "2000",
month = "11",
day = "23",
doi = "10.1023/A:1008379101017",
language = "English (US)",
volume = "11",
pages = "1335--1341",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Pemetrexed

T2 - A multitargeted antifolate agent with promising activity in solid tumors

AU - Adjei, Alex

PY - 2000/11/23

Y1 - 2000/11/23

N2 - Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.

AB - Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.

KW - Multitargeted antifolate

KW - Solid tumors

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=0033758532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033758532&partnerID=8YFLogxK

U2 - 10.1023/A:1008379101017

DO - 10.1023/A:1008379101017

M3 - Article

C2 - 11106124

AN - SCOPUS:0033758532

VL - 11

SP - 1335

EP - 1341

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -